Wild-type (senile) amyloidosis natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 25: | Line 25: | ||
}}</ref> | }}</ref> | ||
*The constellation of [[Medical sign|signs]] and [[Symptom|symptoms]] of a [[Transthyretin|TTR]] affected [[heart]] can mimic [[heart failure]] due to [[old age]], and can thus mask the systemic involvement of wild-type (senile) amyloidosis. | *The constellation of [[Medical sign|signs]] and [[Symptom|symptoms]] of a [[Transthyretin|TTR]] affected [[heart]] can mimic [[heart failure]] due to [[old age]], and can thus mask the systemic involvement of wild-type (senile) amyloidosis. | ||
*If left untreated, wild-type (senile) amyloidosis can lead to [[Heart failure with reduced ejection fraction|heart failure with reduced ejection fraction (HFrEF)]] and eventually death.<ref>{{Cite journal | *If left untreated, wild-type (senile) amyloidosis can lead to [[Heart failure with reduced ejection fraction|heart failure with reduced ejection fraction (HFrEF)]] and eventually death.<ref name=":0">{{Cite journal | ||
| author = [[Belinda Ng]], [[Lawreen H. Connors]], [[Ravin Davidoff]], [[Martha Skinner]] & [[Rodney H. Falk]] | | author = [[Belinda Ng]], [[Lawreen H. Connors]], [[Ravin Davidoff]], [[Martha Skinner]] & [[Rodney H. Falk]] | ||
| title = Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis | | title = Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis | ||
| Line 40: | Line 40: | ||
===Complications=== | ===Complications=== | ||
* Wild-type (senile) amyloidosis is most commonly complicated by [[Heart failure with reduced ejection fraction|heart failure with reduced ejection fraction (HFrEF)]].<ref name=":0" /> | |||
* Other [[Complication (medicine)|complications]] include: | |||
** [[Left bundle branch block|Left bundle branch block (LBBB)]] | |||
** [[Peripheral neuropathy]] | |||
** [[Tendon]] [[rupture]] | |||
===Prognosis=== | ===Prognosis=== | ||
Revision as of 19:15, 17 December 2019
|
Wild-type (senile) amyloidosis Microchapters |
|
Differentiating Wild-type (senile) amyloidosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wild-type (senile) amyloidosis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis natural history, complications and prognosis |
|
FDA on Wild-type (senile) amyloidosis natural history, complications and prognosis |
|
CDC on Wild-type (senile) amyloidosis natural history, complications and prognosis |
|
Wild-type (senile) amyloidosis natural history, complications and prognosis in the news |
|
Blogs on Wild-type (senile) amyloidosis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Natural History, Complications, and Prognosis
Natural History
- In amyloidosis, insoluble fibrils of amyloid are deposited in the organs, causing organ dysfunction and eventually death.[1]
- Wild-type (senile) amyloidosis, as the name suggests, is a disease of the elderly.
- The clinical picture of the disease corresponds to the type of organ or organ system involved.
- It most commonly affects the heart and hence, clinical features pertaining to cardiac pathologies, dominate the clinical course of the disease.
- The deposition of transthyretin (TTR) in the heart causes it to start functionally failing.[2]
- The constellation of signs and symptoms of a TTR affected heart can mimic heart failure due to old age, and can thus mask the systemic involvement of wild-type (senile) amyloidosis.
- If left untreated, wild-type (senile) amyloidosis can lead to heart failure with reduced ejection fraction (HFrEF) and eventually death.[3]
Complications
- Wild-type (senile) amyloidosis is most commonly complicated by heart failure with reduced ejection fraction (HFrEF).[3]
- Other complications include:
Prognosis
References
- ↑ Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
- ↑ Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter
|month=ignored (help) - ↑ 3.0 3.1 Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter
|month=ignored (help)